Yaky Yanay
2021
In 2021, Yaky Yanay earned a total compensation of $9.4M as Chief Executive Officer at Pluristem Therapeutics, a 2,570% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $126,000 |
|---|---|
| Salary | $459,016 |
| Stock Awards | $8,741,402 |
| Other | $27,588 |
| Total | $9,354,006 |
Yanay received $8.7M in stock awards, accounting for 93% of the total pay in 2021.
Yanay also received $126K in non-equity incentive plan, $459K in salary and $27.6K in other compensation.
Rankings
In 2021, Yaky Yanay's compensation ranked 1,163rd out of 12,415 executives tracked by ExecPay. In other words, Yanay earned more than 90.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,163 out of 12,415 | 91st |
Division Manufacturing | 410 out of 5,508 | 93rd |
Major group Chemicals And Allied Products | 148 out of 2,378 | 94th |
Industry group Drugs | 124 out of 2,099 | 94th |
Industry Biological Products, Except Diagnostic Substances | 35 out of 449 | 92nd |
Source: SEC filing on February 27, 2023.
Yanay's colleagues
We found two more compensation records of executives who worked with Yaky Yanay at Pluristem Therapeutics in 2021.
News
Pluristem Therapeutics CEO Yaky Yanay's 2023 pay jumps 111% to $2.7M
May 1, 2024
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019